Mercer Global Advisors’s Ocular Therapeutix OCUL Stock Holding History

Mercer Global Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$362K	Buy	36,859 +17,238	+88%	+$156K	﹤0.01%	2611
2026 Q1	$166K	Buy	+19,621	New	+$187K	﹤0.01%	2896
2020 Q1	–	Sell	-55,837	Closed	-$221K	–	1209
2019 Q4	$221K	Sell	55,837 -40,000	-42%	-$139K	﹤0.01%	1043
2019 Q3	$291K	Buy	95,837 +10,000	+12%	+$44.7K	0.01%	896
2019 Q2	$378K	Sell	85,837 -5,000	-6%	-$18.5K	0.01%	785
2019 Q1	$361K	Buy	+90,837	New	+$365K	0.01%	758

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mercer Global Advisors's OCUL Position: Q2 2026 in Review

Mercer Global Advisors increased its Ocular Therapeutix (OCUL) stake by 88% in Q2 2026, buying an estimated $156K and bringing the position to 36,859 shares worth $362K. The position accounts for ﹤0.01% of the portfolio, ranked #2611.

Mercer Global Advisors first reported a position in OCUL in Q1 2019 and has held it in 6 quarters since. The position peaked at $378K in Q2 2019. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Mercer Global Advisors held 36,859 shares of Ocular Therapeutix worth $362K as of Q2 2026.
Mercer Global Advisors bought 17,238 Ocular Therapeutix shares in Q2 2026, an estimated $156K.
Ocular Therapeutix made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2611 holding.
Mercer Global Advisors first reported a position in Ocular Therapeutix in Q1 2019 and has held it in 6 quarters since.
Mercer Global Advisors's Ocular Therapeutix position peaked at $378K in Q2 2019.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.